Earnings preview: S&N facing another tough quarter
This article was originally published in Clinica
Smith & Nephew is due to reports its first-quarter results on 2 May, with analysts predicting sales of $1.08 billion (flat against last year’s Q1), and adjusted earnings of 18.4¢ per share, down from 19.5¢ in Q1 2012. The company’s orthopedic reconstructive products look set to underperform again, but analysts are expecting a more positive showing from its wound care business.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.